Drugs / BI 3968621
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07851103 | Oct 2026 → Sep 2030 expected | high grade malignant neoplasm | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3968621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07851103 ↗ |
| Route | Oral | “BI 3968621 is taken daily as tablets.” NCT07851103 ↗ |